Kymera Therapeutics (KYMR) Revenue & Revenue Breakdown
Kymera Therapeutics Revenue Highlights
Latest Revenue (Y)
$78.59M
Latest Revenue (Q)
$3.74M
Kymera Therapeutics Revenue by Period
Kymera Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $78.59M | 67.84% |
| 2022-12-31 | $46.83M | -35.71% |
| 2021-12-31 | $72.83M | 114.00% |
| 2020-12-31 | $34.03M | 1059.99% |
| 2019-12-31 | $2.93M | 100.00% |
| 2018-12-31 | - | - |
Kymera Therapeutics generated $78.59M in revenue during NA 2023, up 67.84% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kymera Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $3.74M | -85.42% |
| 2024-06-30 | $25.65M | 149.34% |
| 2024-03-31 | $10.29M | -78.52% |
| 2023-12-31 | $47.88M | 912.80% |
| 2023-09-30 | $4.73M | -71.37% |
| 2023-06-30 | $16.51M | 74.45% |
| 2023-03-31 | $9.47M | -41.35% |
| 2022-12-31 | $16.14M | 68.98% |
| 2022-09-30 | $9.55M | -17.05% |
| 2022-06-30 | $11.51M | 19.66% |
| 2022-03-31 | $9.62M | -37.01% |
| 2021-12-31 | $15.28M | -24.89% |
| 2021-09-30 | $20.34M | 9.81% |
| 2021-06-30 | $18.52M | -0.98% |
| 2021-03-31 | $18.70M | 46.28% |
| 2020-12-31 | $12.79M | -12.03% |
| 2020-09-30 | $14.53M | 342.00% |
| 2020-06-30 | $3.29M | -4.08% |
| 2020-03-31 | $3.43M | 87.02% |
| 2019-12-31 | $1.83M | 92.95% |
| 2019-09-30 | $950.00K | - |
Kymera Therapeutics generated $3.74M in revenue during Q3 2024, up -85.42% compared to the previous quarter, and up 22.65% compared to the same period a year ago.
Kymera Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PRLD | Prelude Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
KYMR Revenue FAQ
What is Kymera Therapeutics’s yearly revenue?
Kymera Therapeutics's yearly revenue for 2023 was $78.59M, representing an increase of 67.84% compared to 2022. The company's yearly revenue for 2022 was $46.83M, representing a decrease of -35.71% compared to 2021. KYMR's yearly revenue for 2021 was $72.83M, representing an increase of 114.00% compared to 2020.
What is Kymera Therapeutics’s quarterly revenue?
Kymera Therapeutics's quarterly revenue for Q3 2024 was $3.74M, a -85.42% decrease from the previous quarter (Q2 2024), and a -20.88% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $25.65M, a 149.34% increase from the previous quarter (Q1 2024), and a 55.33% increase year-over-year (Q2 2023). KYMR's quarterly revenue for Q1 2024 was $10.29M, a -78.52% decrease from the previous quarter (Q4 2023), and a 8.67% increase year-over-year (Q1 2023).
What is Kymera Therapeutics’s revenue growth rate?
Kymera Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 7.91%, and for the last 5 years (2019-2023) was 2578.66%.